Raymond James Downgrades Editas Medicine (EDIT) to Market Perform
Tweet
Share
E-mailGet Alerts EDIT Hot Sheet
Price: $2.85 +1.79%
Rating Summary:
11 Buy, 13 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 4 | Down: 11 | New: 23
Rating Summary:
11 Buy, 13 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 4 | Down: 11 | New: 23
Join SI Premium – FREE
Raymond James analyst Steven Seedhouse downgraded Editas Medicine (NASDAQ: EDIT) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on Editas Medicine click here. For more ratings news on Editas Medicine click here.
Shares of Editas Medicine closed at $2.91 yesterday.
You May Also Be Interested In
- Deutsche Bank Downgrades L'Oreal SA (OR:FP) (LRLCY) to Sell
- Guggenheim Downgrades Apogee Therapeutics Inc (APGE) to Neutral
- Citi Downgrades Sabra Healthcare REIT Inc. (SBRA) to Neutral
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
